## **INCOME ANALYSIS EXPENSE ANALYSIS** TOTAL OPERATIONAL REVENUE\* 25% 26% 15% 32% \$3,187,832 SPECIAL EVENTS INDIVIDUAL ADMINISTRATIVE RESEARCH PROGRAMS (includes Chapter Events, and other Volunteer Fundraising) Including Cell & Tissue Bank, (includes Annual and ONEpossible campaigns) Medical & Research 14% TOTAL EXPENSES OUTREACH AND EDUCATION Diagnostic Testing \$2,911,725 9% PRIVATE FOUNDATIONS 40% RESEARCH GRANTS **PROGRAM** AND CLINICAL TRIALS **RATIO** 80% PROGRAMS \*Above chart excludes net investment losses of \$5,773,600 Net Assets = \$46,824,384, mainly attributable to proceeds from the 2021 sale of the Priority Review Voucher (PRV) issued after FDA approval of lonafarnib as a treatment for Progeria. PRF's 10-year average net assets prior to this historic payment = \$4.63 million. 20% ADMINISTRATIVE AND FUNDRAISING